BELFAST, United Kingdom, Dec. 14, 2023 (GLOBE NEWSWIRE) -- CV6 Therapeutics (‘CV6’), a drug development biotechnology company that specializes in innovative small molecule therapeutics for cancer and ...

Belfast, UK, 2 November 2022 – CV6 Therapeutics (‘CV6’), a drug development biotechnology company that specializes in innovative small molecule therapeutics for cancer and inflammatory diseases, ...

A QUEEN'S University spin-in which has developed a potentially life-saving new cancer treatment is to invest £8 million to take its first anti-cancer drug through a first-in-human clinical trial. CV6 ...

CV6 Therapeutics (NI) Ltd. has secured US$9.2 million to progress its lead oncology asset CV6-168 into a first-in-human phase Ia trial and perform further scientific development work. CV6-168 is a ...

CV6 Therapeutics Ltd. raised $9.2 million in grant and equity funding to move a first-in-class inhibitor of deoxyuridine 5’-triphosphate nucleotidohydrolase (dUTPase) into a phase Ia trial in cancer.

CV6 Therapeutics will conduct further research with Queen’s University Belfast while clinical trials are going on. Belfast-based CV6 Therapeutics has raised £8m to invest in clinical trials and ...

Belfast-based drug development company CV6 Therapeutics said it will invest almost £8 million (€9.3 million) in clinical trials and further development work on its first anti-cancer drug. The funding ...